These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 15665622

  • 1. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
    Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A.
    Cancer Biother Radiopharm; 2004 Dec; 19(6):746-53. PubMed ID: 15665622
    [Abstract] [Full Text] [Related]

  • 2. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.
    Cancer Res; 1999 Aug 01; 59(15):3646-51. PubMed ID: 10446976
    [Abstract] [Full Text] [Related]

  • 3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.
    Int J Oncol; 2005 Apr 01; 26(4):1025-31. PubMed ID: 15753998
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
    Moriai R, Tsuji N, Moriai M, Kobayashi D, Watanabe N.
    Breast Cancer Res Treat; 2009 Sep 01; 117(2):261-71. PubMed ID: 18815881
    [Abstract] [Full Text] [Related]

  • 6. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 01; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 7. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
    Chen J, Power KA, Mann J, Cheng A, Thompson LU.
    Nutr Cancer; 2007 Mar 01; 58(2):162-70. PubMed ID: 17640162
    [Abstract] [Full Text] [Related]

  • 8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Mar 01; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 9. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS, Kraak MM, Crawford S.
    Bull Cancer; 2006 Jul 01; 93(7):E59-66. PubMed ID: 16873071
    [Abstract] [Full Text] [Related]

  • 10. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
    Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY.
    Oncol Rep; 2003 Jul 01; 10(1):141-4. PubMed ID: 12469160
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
    Furlong SJ, Mader JS, Hoskin DW.
    Oncol Rep; 2006 May 01; 15(5):1385-90. PubMed ID: 16596215
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The combination of green tea and tamoxifen is effective against breast cancer.
    Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, Sartippour G, Zhang L, Lu M, Weinberg O, Rao JY, Brooks MN.
    Carcinogenesis; 2006 Dec 01; 27(12):2424-33. PubMed ID: 16785249
    [Abstract] [Full Text] [Related]

  • 16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Dec 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 17. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z, Wang T, Li F.
    Oncology; 2008 Dec 01; 75(3-4):159-68. PubMed ID: 18827493
    [Abstract] [Full Text] [Related]

  • 18. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
    Yu Y, Zhou Q, Hang Y, Bu X, Jia W.
    Cancer; 2007 Jun 01; 109(11):2374-82. PubMed ID: 17464948
    [Abstract] [Full Text] [Related]

  • 19. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells.
    Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X.
    Oncogene; 2008 Feb 28; 27(10):1472-7. PubMed ID: 17767197
    [Abstract] [Full Text] [Related]

  • 20. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R, Cohen PA.
    Endocr Relat Cancer; 2005 Mar 28; 12(1):75-92. PubMed ID: 15788640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.